(Q39576722)

13 September 2017

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo (English)

1 reference

anaplastic thyroid cancer

13 September 2017

0 references

1 reference

Cristina Grange

4

0 references

Nicoletta Fortunati

Nicoletta Fortunati

12

0 references

Maria Graziella Catalano

Maria Graziella Catalano

1

0 references

Sofia Asioli

Sofia Asioli

6

0 references

Benedetta Bussolati

Benedetta Bussolati

5

0 references

author name string

Mariateresa Pugliese

2

1 reference

13 September 2017

Eleonora Gargantini

3

1 reference

13 September 2017

Ornella Bosco

7

1 reference

13 September 2017

Roberta Poli

8

1 reference

13 September 2017

Alessandra Compagnone

9

1 reference

13 September 2017

Andrea Bandino

10

1 reference

13 September 2017

Franco Mainini

11

1 reference

13 September 2017

Giuseppe Boccuzzi

13

1 reference

13 September 2017

language of work or name

English

0 references

publication date

5 May 2011

1 reference

International Journal of Cancer

13 September 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

13 September 2017

130

1 reference

13 September 2017

3

1 reference

13 September 2017

694-704

1 reference

Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors

13 September 2017

1 reference

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.

21 January 2018

1 reference

Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.

21 January 2018

1 reference

Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways

21 January 2018

1 reference

Histone deacetylase inhibitors that target tubulin

21 January 2018

1 reference

Novel histone deacetylase inhibitors in the treatment of thyroid cancer

21 January 2018

1 reference

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification

21 January 2018

1 reference

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

21 January 2018

1 reference

The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).

21 January 2018

1 reference

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors

21 January 2018

1 reference

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

21 January 2018

1 reference

Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.

21 January 2018

1 reference

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

Taxol stabilizes microtubules in mouse fibroblast cells

21 January 2018

1 reference

Microtubules, microtubule-interfering agents and apoptosis.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26057

1 reference

release_tub4kf2xkbbohdskauvc4rgb34

13 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tub4kf2xkbbohdskauvc4rgb34

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference